Compare DexCom, Inc. (DXCM) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs F5 Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while F5 Inc trades at $480.89 (market cap $26.14B). The key difference: DexCom, Inc. is the larger of the two by market cap, and F5 Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and F5 Inc for 38 Days on average.
| DXCM | FFIV | |
|---|---|---|
Market Cap | $31.86B | $26.14B |
Volume | 3,607,070 | 503,146 |
Sector | Health | Technology |
52-Week High | $92.34 | $469.79 |
52-Week Low | $54.84 | $223.99 |
Typical Hold Time | 62 Days | 38 Days |
Enterprise Value | $31.32B | $24.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
F5 (FFIV) trades at $479.83, up 2.82% today and near its 52-week high, reflecting strong momentum. The stock shows bullish technical signals with recent earnings beats and robust revenue growth, reaching $3.09 billion in 2025. Positive sentiment is driven by leadership in AI security and strategic partnerships, though valuation multiples like a P/E of 36.78 suggest premium pricing. Cash flow remains healthy with $268 million net inflow in 2025, supporting operational strength.
Outlook is cautiously optimistic with growth in AI and security markets offering upside, but risks include high valuation and competitive pressures. Analysts are mixed with a $416.60 consensus target below current price, indicating potential overvaluation. Investors should weigh solid fundamentals against elevated multiples for balanced risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
